Pharmaceuticals Product List and Ranking from 5 Manufacturers, Suppliers and Companies | IPROS

Last Updated： Aggregation Period:Mar 04, 2026～Mar 31, 2026
This ranking is based on the number of page views on our site.

Pharmaceuticals Manufacturer, Suppliers and Company Rankings

Last Updated： Aggregation Period:Mar 04, 2026～Mar 31, 2026
This ranking is based on the number of page views on our site.

  1. マーケットリサーチセンター Tokyo//Service Industry
  2. Tohoku Techno Arch Co., Ltd. Miyagi//Educational and Research Institutions
  3. 富士ロジテックグループ Tokyo//Warehousing and transport related industries
  4. 日本計画研究所 Tokyo//others
  5. ソフトブレーン 東京本社 Tokyo//others
Go to Company Ranking

Pharmaceuticals Product ranking

Last Updated： Aggregation Period:Mar 04, 2026～Mar 31, 2026
This ranking is based on the number of page views on our site.

  1. World Ophthalmic Pharmaceutical Market Research Report 2022-2031 マーケットリサーチセンター
  2. Tohoku Univ. Technology：Nucleic acid molecules that increase insulin-secreting beta cells：T14-170 Tohoku Techno Arch Co., Ltd.
  3. [Seminar] The Current Status of Biopharmaceuticals Including Vaccines in Our Country 日本計画研究所
  4. [Seminar] Ministry of Health, Labour and Welfare: Future Prospects of the Generic Pharmaceutical Industry 日本計画研究所
  5. 4 Overview of Pharmaceutical GDP/GMP Operations Fujilogistic Holdings 富士ロジテックグループ

Pharmaceuticals Product List

1～7 item / All 7 items

Displayed results
Tohoku Univ. Technology：Nucleic acid molecules that increase insulin-secreting beta cells：T14-170

Tohoku Univ. Technology：Nucleic acid molecules that increase insulin-secreting beta cells：T14-170

New treatment concept for diabetes mellitus

　It has been reported that reduction or deletion of Langerhans β cells (hereafter β cells) in pancreatic islet occurs not only in type 1 diabetes but also in type 2 diabetes. Therefore, regeneration or promotion of β cells has been proposed as a promising treatment for diabetes. Recently, it has been shown that the transplantation of bone marrow cells promotes the proliferation of β cells. However, the mechanism is not clear.　 　The present invention relates to nucleic acid molecules that promote the proliferation of β cells. Said molecules increased insulin secretion and decreased blood glucose levels in animal model (right figure and related literature) in vivo. In combination with drug delivery systems, it is expected to establish a novel treatment for diabetes.

  • others
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Seminar] The Current Status of Biopharmaceuticals Including Vaccines in Our Country

[Seminar] The Current Status of Biopharmaceuticals Including Vaccines in Our Country

Know-how for acquiring subsidies for the establishment of domestic development and manufacturing bases.

Our company will hold a seminar titled "Current Status of Biopharmaceuticals Including Vaccines in Our Country." In light of the spread of the novel coronavirus, the establishment of development and manufacturing bases for biopharmaceuticals, including vaccines, in Japan has been recognized by the government as an urgent issue from the perspective of not only public health but also risk management for national security. Therefore, this seminar will provide detailed explanations on global market trends for vaccines and biopharmaceuticals, policies related to the establishment of biopharmaceutical bases in our country, and know-how for acquiring subsidies that companies can utilize when participating in the establishment of these bases. [Seminar Details] ■ Date and Time: May 30 (Thursday) 13:30 - 15:30 (Doors open at 13:00) ■ Venue: JPI Conference Square ■ Address: 5-2-32 Minamiazabu, Minato-ku, Tokyo, Kowa Hiroo Building ■ Instructors: Mizuho Research & Technologies Co., Ltd. Social Policy Consulting Department, Social Resilience Promotion Team Chief Consultant: Eri Nichiro Consultant: Yuki Sato *For more details, please refer to the PDF document or feel free to contact us.

  • others
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
[Seminar] Ministry of Health, Labour and Welfare: Future Prospects of the Generic Pharmaceutical Industry

[Seminar] Ministry of Health, Labour and Welfare: Future Prospects of the Generic Pharmaceutical Industry

Discussion content in the "Study Group on the Structure of Industry for Achieving Stable Supply of Generic Pharmaceuticals, etc."

Our company will hold a seminar titled "Ministry of Health, Labour and Welfare: Future Prospects of the Generic Pharmaceutical Industry." Generic pharmaceuticals account for over 50% of the total quantity of prescription drugs and contribute to the improvement of healthcare financing, playing an essential role as social infrastructure. On the other hand, in response to the supply shortage of generic pharmaceuticals triggered by regulatory actions against certain generic pharmaceutical companies, a study group titled "Study on the Structure of the Industry for Achieving Stable Supply of Generic Pharmaceuticals" was established in July 2023 to engage in broad discussions on the ideal state of the generic pharmaceutical industry and the industrial policies needed to realize it. This seminar will provide detailed explanations not only of the discussions from this study group but also of the future prospects of the generic pharmaceutical industry. 【Seminar Details】 ■ Date and Time: June 13 (Thursday) 13:30 - 15:30 (Doors open at 13:00) ■ Venue: JPI Conference Square ■ Speaker: Ministry of Health, Labour and Welfare Member of the "Study on the Structure of the Industry for Achieving Stable Supply of Generic Pharmaceuticals" Director of the Healthcare Division, Corporate Finance Department 6, Development Bank of Japan Mr. Masafumi Nozawa *For more details, please refer to the PDF document or feel free to contact us.

  • others
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Overview of Pharmaceutical GDP/GMP Operations Fujilogistic Holdings

Overview of Pharmaceutical GDP/GMP Operations Fujilogistic Holdings

Confident in our know-how: We can provide services tailored to our customers' needs under various business licenses!

This document introduces an overview of the operation of pharmaceutical GDP/GMP. It includes various content such as "business licenses," "examples of medical pharmaceutical supply chains," operational and transportation flows, and case studies from manufacturing and sales, accompanied by photos and tables. The content is designed to be easily referenced when considering implementation. Please feel free to download and take a look. 【Contents (partial)】 ■ Business Licenses ■ Examples of Medical Pharmaceutical Supply Chains ■ Examples of Veterinary Pharmaceutical Supply Chains ■ Life Sciences ■ Case Studies *For more details, please refer to the PDF document or feel free to contact us.

  • Analysis and prediction system
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
What strategies should be implemented in response to changes in customer behavior during the COVID-19 pandemic?

What strategies should be implemented in response to changes in customer behavior during the COVID-19 pandemic?

Explaining examples that provide hints for developing marketing strategies in response to customer behavior during the COVID-19 pandemic!

Several months have passed since the state of emergency was declared due to the spread of the novel coronavirus, yet the end is still not in sight. As the second and third waves hit, companies are facing a pressing situation where they can no longer afford to stall their business activities. Here, we will consider customer behavior during the pandemic and think of examples that can serve as hints for developing marketing strategies in response. *For detailed content of the column, please refer to the related link. For more information, feel free to contact us.*

  • SFA (Sales Support System)
  • Online business negotiation system
  • Ad management and operations
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Ophthalmic Pharmaceutical Market Research Report 2022-2031

World Ophthalmic Pharmaceutical Market Research Report 2022-2031

Global Market for Ophthalmic Pharmaceuticals 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research materials from Transparency Market Research comprehensively investigate and analyze the global ophthalmic pharmaceuticals market, including sections on introduction, assumptions and research methods, market overview, key insights, disease-specific analysis (dry eye, glaucoma, infections & inflammation, retinal diseases, others), treatment category analysis (anti-inflammatory agents, anti-infectives, glaucoma treatments, anti-allergics, others), product type analysis (prescription pharmaceuticals, OTC drugs), distribution channel analysis (hospital pharmacies, online pharmacies, independent pharmacies & drugstores), regional analysis (North America, Latin America, Europe, Asia-Pacific, Middle East/Africa), competitive landscape, and company information.

  • others
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Market Research Report on Central Nervous System Pharmaceuticals Worldwide (up to 2027)

Market Research Report on Central Nervous System Pharmaceuticals Worldwide (up to 2027)

Global Central Nervous System Pharmaceuticals Market (up to 2027): By Drug Classification, By Disease, By Region

The market research report by 360iResearch predicts that the global market size for central nervous system pharmaceuticals will grow from $61.94 billion in 2021 to $67.44 billion in 2022, and further increase at an average annual rate of 9.13% to reach $104.66 billion by 2027. This report provides a comprehensive analysis of the global market for central nervous system pharmaceuticals, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by drug classification (analgesics, anesthetics, anticonvulsants, anti-Parkinson's drugs, antidepressants), analysis by disease (central nervous system trauma, infections, mental health, neurodegenerative diseases, neurovascular diseases), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • Pharmaceuticals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.